阿维A胶囊对肺癌患者血清中EGFR、LRP等血清指标的影响及临床意义分析

Effect of acitretin on serum LRP,EGFR and clinical analysis in patients with lung cancer

目的探讨阿维A胶囊对肺癌患者血清中EGFR、LRP、CEA、NSE及CYFRA21-1等的影响及临床意义分析。方法将251例晚期非小细胞肺癌患者分成四组,观察其用药前后血清中LRP、EGFR等含量的变化。结果治疗A组较对照A组血清指标下降明显(P<0.05),治疗A组化疗无效者与治疗B组患者血清指标下降幅度接近(P<0.05),对照A组化疗无效者与对照B组血清指标均升高(P<0.05)。结论阿维A胶囊有改变肿瘤恶性程度,并使血清肿瘤标志物水平降低的可能,为探索临床应用分化诱导剂治疗肿瘤的新途径提供临床依据。

Objective To investigate the change of serum tumor makers of LRP,EGFR,CEA,NSE and CYFRA21-1,after acitretin in treatment of lung cancer and clinical significance.Methods 251 cases of advanced non-small cell lung cancer patients were randomly divided into four groups,four cycles of treatment were observed before and after treatment serum LRP,EGFR,CEA,NSE and CYFRA21-1 levels change.Results A result of the treatment group than in the control group A in serum were decreased significantly（P〈0.05）,ineffective chemotherapy treatment group A and group B patients treated drop close to the target（P〈0.05）,ineffective chemotherapy control group A and group B serum markers were elevated（P〈0.05）.Conclusion Avermectin A capsules have changed malignancy,and to reduce the level of serum tumor markers in the possibility to explore the clinical application of differentiation inducer and further to provide new ways to treat cancer clinical basis.